Analysis

4 Key Takeaways As Historic Opioid Ruling Wallops J&J

Law360 (August 26, 2019, 10:52 PM EDT) -- Johnson & Johnson's historic loss in the nation's first opioid-crisis trial erases any doubt that Big Pharma faces staggering exposure from a wave of opioid litigation and will likely expand public scrutiny beyond familiar targets like OxyContin seller Purdue Pharma.

J&J's emphatic defeat came in an Oklahoma judge's decision Monday that found J&J and its Janssen Pharmaceuticals Inc. unit "engaged in false and misleading marketing" of prescription opioids and must pay $572 million to remedy an ensuing addiction epidemic in the Sooner State.

There are important caveats regarding the decision's significance: J&J immediately vowed to appeal, the decision stemmed from a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!